查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1494683

基因生物标誌物市场：按产品类型、适应症和最终用户划分 - 全球预测 2024-2030

Genomic Biomarker Market by Product (Consumables, Services, Software), Type (Predictive Biomarkers, Prognostic Biomarkers), Disease Indication, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年基因生物标誌物市场规模为44亿美元，预计2024年将达46.7亿美元，2030年将达到69.2亿美元，复合年增长率为6.67%。

基因生物标誌物是DNA或RNA分子，用于检查基因与环境之间的复杂关係，大大增强了对健康、疾病和农产品的理解和管理。这些生物标记在早期疾病诊断和风险评估中发挥着至关重要的作用，使得在症状出现之前更容易识别潜在的健康问题，例如癌症和心血管疾病。基因生物标誌物提供个人化医疗，允许根据每个人的基因图谱客製化治疗，优化治疗效果并最大限度地减少副作用。製药领域在开发特异性针对疾病分子基础的标靶药物中从基因生物标誌物中受益匪浅。在农业中，基因生物标誌物能够培育出提高产量并抵抗环境压力的作物品种。基因生物标誌物广泛应用于农业研究、医疗保健和农业。随着基因组标记在个人化医疗中的应用不断扩大，医疗保健和製药领域对基因生物标誌物的需求正在迅速增加。此外，政府对基因生物标誌物研究和开发的监管支持不断增加，正在推动对先进、更有效的基因生物标誌物的需求。然而，与这些生物标誌物开发相关的技术限制阻碍了需求。此外，将机器学习和人工智慧整合到基因组研究中将增强基因生物标誌物的预测能力。

主要市场统计
基准年[2023] 44亿美元
预测年份 [2024] 46.7亿美元
预测年份 [2030] 69.2亿美元
复合年增长率（%） 6.67%

区域洞察

由于医疗基础设施的改善和生物医学研究投资的大幅增加，美洲，尤其是北美，对基因生物标誌物的需求强劲。由于该地区癌症和心血管疾病等慢性疾病的高盛行率，个人化医疗方法正在扩大基因生物标誌物的应用。此外，研究机构和生技公司之间的持续合作将加强基因生物标誌物的创新，支持政府的基因组研究资助政策，并规范进展以扩大马苏地区的需求。由于医疗保健和诊断领域的快速扩张，该地区的基因生物标誌物市场正在快速成长。在中国、日本、韩国等国家，生物技术领域正在快速发展，对基因生物标誌物有强烈需求。医疗保健支出的增加、个人化医疗意识的提高以及公共和私人对基因组研究投资的增加是关键驱动因素。由于先进医疗保健系统和次世代定序仪技术的普及，欧洲和中东地区正在呈现快速成长。在欧盟 (EU)，由于政府对基因组研究和国家间合作研究的资助，基因生物标誌物的引入显着扩大。由于更加重视改善医疗保健系统以及增加对医疗保健产业的外国投资，非洲地区具有成长潜力。

FPNV定位矩阵

FPNV 定位矩阵对于评估基因生物标誌物市场供应商的市场定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对基因生物标誌物市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外，该分析还提供了对该行业竞争性质的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在基因生物标誌物市场中的地位进行全面评估，使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 更多地使用基因生物标誌物来早期检测和诊断慢性疾病
      • 政府和监管部门对基因生物标誌物研究的支持
      • 扩大基因生物标誌物在个人化医疗的应用
    • 抑制因素
      • 与开发基因生物标誌物相关的高成本和技术问题
    • 机会
      • 整合人工智慧、机器学习和基因组研究
      • 人们对开发先进的非侵入性基因生物标誌物越来越感兴趣
    • 任务
      • 关于使用基因生物标誌物的伦理和法律问题
  • 市场区隔分析
    • 类型：扩大预后生物标记在药物研究中的使用
    • 最终使用者：扩大基因生物标誌物在诊断中心的应用
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章基因生物标誌物市场：副产品

  • 消耗品
  • 服务
  • 软体

第七章基因生物标誌物市场：依类型

  • 预测生物标记
  • 预后生物标记

第八章基因生物标誌物市场：依疾病指示

  • 心血管疾病
  • 神经系统疾病
  • 肿瘤学
  • 肾臟疾病

第 9 章基因生物标誌物市场：依最终用户分类

  • 诊断中心
  • 医院
  • 调查机构

第10章美洲基因生物标誌物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区基因生物标誌物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的基因生物标誌物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • Bio-Rad 推出创新的多重数位 PCR 检测以增强乳癌监测
    • 使用 Biofidelity 的 ASPYRE-Lung RUO 试剂增强快速基因生物标誌物分析简介
    • Illumina 在肿瘤学领域取得突破 TruSight Oncology 500 ctDNA v2 为固态肿瘤基因组分析提供支持
  • 战略分析和建议

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-CB04E0565332

[194 Pages Report] The Genomic Biomarker Market size was estimated at USD 4.40 billion in 2023 and expected to reach USD 4.67 billion in 2024, at a CAGR 6.67% to reach USD 6.92 billion by 2030.

Genomic biomarkers are DNA or RNA molecules that are used to examine the complex relationships between genetics and the environment and significantly enhance understanding and management of health, diseases, and agricultural outputs. These biomarkers play a pivotal role in early disease diagnosis and risk assessment, facilitating the identification of potential health issues such as cancer and cardiovascular diseases before they manifest symptoms. Genomic biomarkers offer personalized medicine and enable the customization of treatments to each individual's genetic profile, optimizing therapy effectiveness and minimizing adverse effects. The pharmaceutical sector benefits immensely from genomic biomarkers in the development of targeted medications that specifically address the molecular basis of diseases. In agriculture, they enable the breeding of crop varieties with enhanced yields and resistance to environmental stresses. Genomic biomarkers are widely used in agricultural research, healthcare, and farming practices. The growing applications of genomic markers for personalized medicine are surging the need for genomic biomarkers in the healthcare and pharmaceutical sectors. Additionally, the growing regulatory support by the governments for research and development of genomic biomarkers is driving the demand for advanced and more effective genomic biomarkers. However, technical limitations associated with the development of these biomarkers hinder the demand. Moreover, the integration of machine learning and AI with genomic studies enhances the predictive ability of genomic biomarkers.

KEY MARKET STATISTICS
Base Year [2023] USD 4.40 billion
Estimated Year [2024] USD 4.67 billion
Forecast Year [2030] USD 6.92 billion
CAGR (%) 6.67%

Regional Insights

In the Americas, particularly North America, is exhibiting a robust demand for genomic biomarkers with the well-established healthcare infrastructure and a significant increase in investments in biomedical research. With a high prevalence of chronic diseases such as cancer and cardiovascular diseases within the region, personalized medicine approaches are thus increasing the application of genomic biomarkers. Moreover, ongoing collaborations between research institutes and biotechnology companies enhance the innovation of genomic biomarkers, support government policies on genomics research funds, and regulate advancements to expand the demand within the region. This region is experiencing rapid growth in the genomic biomarker market with the surging expansion of the healthcare and diagnostic sectors. Countries such as China, Japan, and South Korea have robust needs for genomic biomarkers due to their fast-growing biotech sectors. Rising healthcare expenditure, rising awareness about personalized medicine, and an increase in public and private investment in genomic research are important drivers. Europe and the Middle East regions show rapid growth driven by advanced healthcare systems and widespread adoption of next-generation sequencing technologies. Government funding in genomics and collaborations across countries in the European Union are significantly growing the adoption of genomic biomarkers. There is potential growth in the African region due to an increasing focus on improving healthcare systems and rising foreign investments in the healthcare sector.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Genomic Biomarker Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
      • Governments and regulatory support for genomic biomarker research
      • Growing applications of genomic biomarkers in personalized medicine
    • Market Restraints
      • High cost and technical issues associated with developing genomic biomarkers
    • Market Opportunities
      • Integration of AI and machine learning with genomic studies
      • Growing interest in developing advanced noninvasive genomic biomarkers
    • Market Challenges
      • Ethical and legal concerns regarding the use of genomic biomarkers
  • Market Segmentation Analysis
    • Type: Proliferating use of prognostic biomarkers in pharmaceutical research
    • End-user: Expanding application of genomic biomarkers in diagnostic centers
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Genomic Biomarker Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Genomic Biomarker Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Bio-Rad Introduces Revolutionary Multiplexed Digital PCR Assay for Enhanced Breast Cancer Research

Bio-Rad Laboratories, Inc. unveiled its groundbreaking ddPLEX ESR1 Mutation Detection Kit. his kit marks a significant advance in the oncology sector by offering an ultrasensitive, multiplexed digital PCR assay designed to detect, differentiate, and quantitatively assess seven critical ESR1 mutations from a single sample. This development expands Bio-Rad's portfolio in digital PCR solutions and strengthens its commitment to supporting oncology researchers in biomarker discovery and clinical trials, thereby improving patient care continuity and treatment efficacy. [Published On: 2024-04-01]

Biofidelity's Introduction ASPYRE-Lung RUO Reagents for Enhanced and Rapid Genomic Biomarker Analysis

Biofidelity unveiled the ASPYRE-Lung RUO, a cutting-edge reagent product designed to simplify and expedite the detection of genomic biomarkers in labs globally. The ASPYRE-Lung technology uses standard PCR instruments already present in most laboratories, eliminating the need for specialized staff or complex setups. Its high sensitivity facilitates the use of tissue samples with minimal tumor content, considerably lowering the threshold compared to traditional assays. The ASPYRE-Lung RUO is poised to revolutionize diagnostic tests, ensuring high-quality results with quick turnarounds for diverse research applications. [Published On: 2023-12-06]

Illumina's Breakthrough in Oncology TruSight Oncology 500 ctDNA v2 Enhances Solid Tumor Genomic Profiling

Illumina Inc. introduced the latest version of its liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2). This cutting-edge research tool offers noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA), providing critical data when traditional tissue sample testing is not feasible. As Illumina gears up to integrate automation in their assays, this innovation stands poised to redefine the landscape of tumor profiling, rendering it an increasingly indispensable tool in precision oncology. [Published On: 2023-11-01]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Genomic Biomarker Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Genomic Biomarker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocrates Life Sciences AG, Biostarks Laboratories SA, Bruker Corporation, CD Genomics, Charles River Laboratories, Inc., DH Life Sciences, LLC., Elo Health, Inc., Eurofins Scientific corporation, F. Hoffmann-La Roche Ltd, Illumina Inc., Merck KGaA, Myriad Genetics, Inc, Owkin, Inc, and Thermo Fisher Scientific company.

Market Segmentation & Coverage

This research report categorizes the Genomic Biomarker Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Consumables
    • Services
    • Software
  • Type
    • Predictive Biomarkers
    • Prognostic Biomarkers
  • Disease Indication
    • Cardiovascular Diseases
    • Neurological Diseases
    • Oncology
    • Renal Disorders
  • End-User
    • Diagnostic Centers
    • Hospitals
    • Research Institutions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
      • 5.1.1.2. Governments and regulatory support for genomic biomarker research
      • 5.1.1.3. Growing applications of genomic biomarkers in personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and technical issues associated with developing genomic biomarkers
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of AI and machine learning with genomic studies
      • 5.1.3.2. Growing interest in developing advanced noninvasive genomic biomarkers
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and legal concerns regarding the use of genomic biomarkers
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Proliferating use of prognostic biomarkers in pharmaceutical research
    • 5.2.2. End-user: Expanding application of genomic biomarkers in diagnostic centers
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Genomic Biomarker Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Services
  • 6.4. Software

7. Genomic Biomarker Market, by Type

  • 7.1. Introduction
  • 7.2. Predictive Biomarkers
  • 7.3. Prognostic Biomarkers

8. Genomic Biomarker Market, by Disease Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases
  • 8.3. Neurological Diseases
  • 8.4. Oncology
  • 8.5. Renal Disorders

9. Genomic Biomarker Market, by End-User

  • 9.1. Introduction
  • 9.2. Diagnostic Centers
  • 9.3. Hospitals
  • 9.4. Research Institutions

10. Americas Genomic Biomarker Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Genomic Biomarker Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Genomic Biomarker Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Bio-Rad Introduces Revolutionary Multiplexed Digital PCR Assay for Enhanced Breast Cancer Research
    • 13.3.2. Biofidelity's Introduction ASPYRE-Lung RUO Reagents for Enhanced and Rapid Genomic Biomarker Analysis
    • 13.3.3. Illumina's Breakthrough in Oncology TruSight Oncology 500 ctDNA v2 Enhances Solid Tumor Genomic Profiling
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. GENOMIC BIOMARKER MARKET RESEARCH PROCESS
  • FIGURE 2. GENOMIC BIOMARKER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GENOMIC BIOMARKER MARKET DYNAMICS
  • FIGURE 7. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. GENOMIC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. GENOMIC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENOMIC BIOMARKER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RENAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RENAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 327. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 328. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 335. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 336. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 344. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 351. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 352. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 353. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 354. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 355. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 356. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 357. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 358. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MIL